Navigation Links
Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
Date:2/11/2009

ALISO VIEJO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that it will host a conference call on Tuesday, February 24, 2009 at 11:00 a.m. EST (8:00 a.m. PST) to discuss results for the 2008 fourth quarter and year.

The dial-in number to participate on this call is (877) 295-5743, confirmation code 83660030. International callers should dial (973) 200-3961, confirmation code 83660030. A replay will be available approximately two hours following the conclusion of the conference call to Tuesday, March 3, 2009, and can be accessed by dialing (800) 642-1687 or (706) 645-9291, confirmation code 83660030.

The company also will webcast the call live over the Internet, which will be hosted in the investor relations section of its corporate Web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the Internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

    Contact:
    Laurie W. Little, Valeant Pharmaceuticals
    949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
4. Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals
5. Mpex Pharmaceuticals Announces Series D Financing of Up to $40 Million
6. Prism Pharmaceuticals Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
7. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
8. Pharmaceuticals sold in Sweden cause serious environmental harm in India
9. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
10. Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
11. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... New Orleans, LA (PRWEB) , ... December 07, ... ... cosmetic technique used to treat wrinkles and deep lines by smoothing and tightening ... many minimally invasive techniques out there to address facial aging with very little ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 million (net ... Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... Castle ... used in several ways to restore a more youthful appearance to the face. Dr. ... offer Sculptra, along with a variety of other treatments, to rejuvenate and renew the ...
(Date:12/7/2016)... , ... December 07, 2016 , ... They are musicians ... sisters and wives, brothers and fathers, from New England and around the nation. What ... stigma, and are brought together in a beautiful and compelling new photographic exhibit debuting ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... consultation services from offices located in South Lyon, Dewitt, Williamston, East Lansing, Ann ... basketball coach who needs treatment for a brain tumor. , Jason Bauer and ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Dec. 7, 2016   IQuity, Inc., a ... Don Hardison has been appointed to ... executive with extensive experience as CEO, COO, and ... 500 companies within the molecular, clinical diagnostic, and ... and sales experience within the pharmaceutical industry. His ...
(Date:12/7/2016)... 2016  Urinary catheters are used for patients ... urological disorders. Urinary catheters include indwelling (Foley) catheter, ... or Foley catheter is a flexible tube with ... is inserted into the bladder through the urethra ... attachment at one end of the catheter is ...
(Date:12/7/2016)... Research and Markets has announced the addition of the "Immunohistochemistry Market ... report to their offering. ... The immunohistochemistry (IHC) market is projected ... 7.3% during the forecast period of 2016 to 2021. ... population across the globe are the primary driving the growth of this ...
Breaking Medicine Technology: